Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
HRMY Quote, Financials, Valuation and Earnings
Last price:
$29.15
Seasonality move
:
-13.96%
Day range:
$28.00 - $34.00
52-week range:
$25.52 - $40.87
Dividend yield:
0%
P/E ratio:
9.18x
P/S ratio:
2.06x
P/B ratio:
2.01x
Volume:
5.4M
Avg. volume:
820.4K
1-year change:
-16.42%
Market cap:
$1.7B
Revenue:
$714.7M
EPS (TTM):
$3.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$240.3M | $1.13 | 22.43% | 47.81% | $46.73 |
|
CSTL
Castle Biosciences, Inc.
|
$80.3M | -$0.26 | -12.07% | -55.29% | $48.13 |
|
INSM
Insmed, Inc.
|
$264M | -$1.17 | 225.21% | -34.8% | $212.95 |
|
LQDA
Liquidia Corp.
|
$83.7M | $0.27 | 3062.5% | -50.89% | $43.00 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$312.7M | -$0.88 | 119.49% | -10.8% | $667.57 |
|
PTCT
PTC Therapeutics, Inc.
|
$289.2M | -$0.41 | -80.52% | -52.54% | $87.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$29.16 | $46.73 | $1.7B | 9.18x | $0.00 | 0% | 2.06x |
|
CSTL
Castle Biosciences, Inc.
|
$29.21 | $48.13 | $852.6M | 30.24x | $0.00 | 0% | 2.50x |
|
INSM
Insmed, Inc.
|
$164.91 | $212.95 | $35.2B | -- | $0.00 | 0% | 54.09x |
|
LQDA
Liquidia Corp.
|
$33.59 | $43.00 | $2.9B | -- | $0.00 | 0% | 41.47x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$435.01 | $667.57 | $9.9B | -- | $0.00 | 0% | 10.17x |
|
PTCT
PTC Therapeutics, Inc.
|
$70.66 | $87.93 | $5.7B | 9.13x | $0.00 | 0% | 3.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
21.38% | 0.442 | 14.3% | 3.46x |
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 0.721 | 5.59% | 6.09x |
|
INSM
Insmed, Inc.
|
50.57% | 2.488 | 2.04% | 3.35x |
|
LQDA
Liquidia Corp.
|
90.03% | -0.017 | 10.09% | 1.88x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
36.58% | -0.430 | 2.63% | 3.62x |
|
PTCT
PTC Therapeutics, Inc.
|
206.17% | 0.479 | 6.54% | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$173.8M | $65.5M | 19.81% | 25.9% | 27.35% | $108.7M |
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
LQDA
Liquidia Corp.
|
$50.9M | $1.8M | -79.94% | -221.75% | 3.25% | -$10.7M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$296.2M | -$59.6M | -32.42% | -42.53% | -18.57% | -$133.1M |
|
PTCT
PTC Therapeutics, Inc.
|
$148.4M | -$81.6M | 2742.58% | -- | -49.57% | -$71.6M |
Harmony Biosciences Holdings, Inc. vs. Competitors
-
Which has Higher Returns HRMY or CSTL?
Castle Biosciences, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -0.6%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Castle Biosciences, Inc.'s return on equity of -2.71%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M -
What do Analysts Say About HRMY or CSTL?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.73, signalling upside risk potential of 60.24%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $48.13 which suggests that it could grow by 64.76%. Given that Castle Biosciences, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.6 2 0 CSTLCastle Biosciences, Inc.8 0 0 -
Is HRMY or CSTL More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.838, which suggesting that the stock is 16.16% less volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.16%.
-
Which is a Better Dividend Stock HRMY or CSTL?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or CSTL?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 9.18x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.06x versus 2.50x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.06x 9.18x $239.5M $50.9M CSTLCastle Biosciences, Inc.2.50x 30.24x $83M -$501K
-
Which has Higher Returns HRMY or INSM?
Insmed, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -124.5%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About HRMY or INSM?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.73, signalling upside risk potential of 60.24%. On the other hand Insmed, Inc. has an analysts' consensus of $212.95 which suggests that it could grow by 29.13%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Insmed, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.6 2 0 INSMInsmed, Inc.17 1 0 -
Is HRMY or INSM More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.838, which suggesting that the stock is 16.16% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock HRMY or INSM?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or INSM?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 9.18x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.06x versus 54.09x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.06x 9.18x $239.5M $50.9M INSMInsmed, Inc.54.09x -- $263.8M -$328.5M
-
Which has Higher Returns HRMY or LQDA?
Liquidia Corp. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -6.5%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Liquidia Corp.'s return on equity of -221.75%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B LQDALiquidia Corp.93.65% -$0.04 $221.2M -
What do Analysts Say About HRMY or LQDA?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.73, signalling upside risk potential of 60.24%. On the other hand Liquidia Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 28.01%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Liquidia Corp., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Liquidia Corp..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.6 2 0 LQDALiquidia Corp.6 0 1 -
Is HRMY or LQDA More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.838, which suggesting that the stock is 16.16% less volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.687%.
-
Which is a Better Dividend Stock HRMY or LQDA?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or LQDA?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Liquidia Corp. quarterly revenues of $54.3M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Liquidia Corp.'s net income of -$3.5M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 9.18x while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.06x versus 41.47x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.06x 9.18x $239.5M $50.9M LQDALiquidia Corp.41.47x -- $54.3M -$3.5M
-
Which has Higher Returns HRMY or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -18.24%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B MDGLMadrigal Pharmaceuticals, Inc.92.26% -$2.57 $950.3M -
What do Analysts Say About HRMY or MDGL?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.73, signalling upside risk potential of 60.24%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $667.57 which suggests that it could grow by 53.46%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.6 2 0 MDGLMadrigal Pharmaceuticals, Inc.11 2 0 -
Is HRMY or MDGL More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.838, which suggesting that the stock is 16.16% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.
-
Which is a Better Dividend Stock HRMY or MDGL?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or MDGL?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 9.18x while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.06x versus 10.17x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.06x 9.18x $239.5M $50.9M MDGLMadrigal Pharmaceuticals, Inc.10.17x -- $321.1M -$58.6M
-
Which has Higher Returns HRMY or PTCT?
PTC Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -81.96%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M -
What do Analysts Say About HRMY or PTCT?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.73, signalling upside risk potential of 60.24%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $87.93 which suggests that it could grow by 24.44%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.6 2 0 PTCTPTC Therapeutics, Inc.7 4 1 -
Is HRMY or PTCT More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.838, which suggesting that the stock is 16.16% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.641%.
-
Which is a Better Dividend Stock HRMY or PTCT?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or PTCT?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than PTC Therapeutics, Inc. quarterly revenues of $164.7M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than PTC Therapeutics, Inc.'s net income of -$135M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 9.18x while PTC Therapeutics, Inc.'s PE ratio is 9.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.06x versus 3.39x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.06x 9.18x $239.5M $50.9M PTCTPTC Therapeutics, Inc.3.39x 9.13x $164.7M -$135M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
